Akums Drugs

When is the next results date for Akums Drugs?

No Upcoming Board Meetings

Has Akums Drugs declared dividend?

No Dividend History Available

Who are the peers of the Akums Drugs?

Akums Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shilpa Medicare, Aarti Pharma, Strides Pharma, FDC, and SPARC. In terms of management risk, growth, and capital structure, Sun Pharma and Cipla are top performers, while Akums Drugs shows average management risk and below-average growth.

Peers: The peers of Akums Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shilpa Medicare, Aarti Pharma, Strides Pharma, FDC, and SPARC.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Akums Drugs, Shilpa Medicare, Aarti Pharma, and FDC. Below Average management risk is noted for Strides Pharma and SPARC. For Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is reported for Akums Drugs, Divi's Lab., Torrent Pharma, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC. Finally, Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, and Aarti Pharma, while Good capital structure is noted for Torrent Pharma and Akums Drugs, and Below Average capital structure is seen at Shilpa Medicare, Strides Pharma, and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is SPARC at -7.40%. Akums Drugs does not have a 1-year return available for comparison. Additionally, the peers with negative six-month returns include Torrent Pharma, FDC, and SPARC.

Is Akums Drugs overvalued or undervalued?

As of May 28, 2025, Akums Drugs is considered an attractive investment due to its undervalued status, with a PE ratio of 27.65, lower than peers like Sun Pharmaceutical and Divi's Laboratories, despite a year-to-date return of -11.07% compared to the Sensex's 5.54%.

As of 28 May 2025, the valuation grade for Akums Drugs has moved from does not qualify to attractive, indicating a significant improvement in its investment appeal. The company is currently assessed as undervalued. Key ratios include a PE ratio of 27.65, an EV to EBITDA of 18.09, and a ROCE of 12.16%. <BR><BR>In comparison to its peers, Akums Drugs has a lower PE ratio than Sun Pharmaceutical Industries Ltd., which stands at 35.25, and Divi's Laboratories Ltd., which is at 79.33. Other attractive peers include Cipla Ltd. with a PE of 22.99 and Dr. Reddy's Laboratories Ltd. at 19.49, further supporting the notion that Akums Drugs is undervalued within its sector. Despite a recent underperformance compared to the Sensex, with a year-to-date return of -11.07% against the Sensex's 5.54%, the company's valuation metrics suggest a favorable investment opportunity.

What does Akums Drugs do?

Akums Drugs and Pharmaceuticals Ltd is a mid-cap pharmaceutical CDMO, incorporated in 2004, with net sales of ₹10,556 Cr and a net profit of ₹1,476 Cr as of March 2025. The company has a market cap of ₹8,828 Cr and a P/E ratio of 27.00.

Overview: <BR>Akums Drugs and Pharmaceuticals Ltd is a pharmaceutical contract development and manufacturing organization (CDMO) operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History: <BR>The company was incorporated on April 19, 2004, and received its Certificate for Commencement of Business on May 13, 2004. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 10,556 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,476 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 8,828 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.16 <BR>Return on Equity: 10.55% <BR>Price to Book: 2.89 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Akums Drugs?

The top shareholders of Akums Drugs include Akums Master Trust (40.79%), mutual funds (6.11%), foreign institutional investors (5.77%), and Ruby Qc Investment Holdings Pte Ltd (4.62%), with individual investors holding 3.41%. There are no pledged promoter holdings.

The top shareholders of Akums Drugs include the promoters, with Akums Master Trust, represented by Sanjeev Jain and Sandeep Jain, holding the largest share at 40.79%. There are no pledged promoter holdings. Additionally, mutual funds hold a total of 6.11% across 18 schemes, and foreign institutional investors (FIIs) account for 5.77% through 50 different FIIs. The highest public shareholder is Ruby Qc Investment Holdings Pte Ltd, which holds 4.62%. Individual investors collectively own 3.41% of the company.

How big is Akums Drugs?

As of 24th July, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,578.00 Cr, with recent net sales of 4,118.16 Cr and a net profit of 338.18 Cr. Shareholder's funds are 3,047.01 Cr, and total assets are 3,905.38 Cr.

As of 24th July, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,578.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4,118.16 Cr and a Net Profit of 338.18 Cr.<BR><BR>For the latest annual period ending March 2025, Shareholder's Funds amounted to 3,047.01 Cr, while Total Assets were reported at 3,905.38 Cr.

Is Akums Drugs technically bullish or bearish?

As of October 10, 2025, Akums Drugs shows a mildly bearish trend due to bearish weekly MACD and KST, despite bullish weekly and monthly RSI readings indicating some underlying strength.

As of 10 October 2025, the technical trend for Akums Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST being bearish, alongside daily moving averages indicating a bearish trend. However, the weekly and monthly RSI readings are bullish, suggesting some underlying strength. The Bollinger Bands and OBV are also mildly bearish on a weekly basis. Overall, while there are bullish signals from the RSI, the prevailing indicators lean towards a mildly bearish outlook.

How has been the historical performance of Akums Drugs?

Akums Drugs has shown significant recovery and growth, with net sales reaching 4,118.16 crore in March 2025, up from 3,654.82 crore in March 2023, and a profit after tax of 343.78 crore, recovering from a loss the previous year. The company's financial position is stable, with improved cash flow and earnings per share increasing to 22.09.

Answer:<BR>The historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected this positive trend, reaching 338.18 crore in March 2025, a recovery from a loss of 4.04 crore in March 2024. The company's earnings per share (EPS) improved significantly to 22.09 in March 2025 from -0.28 in March 2024. On the balance sheet, total assets increased to 3,905.38 crore in March 2025 from 3,393.30 crore in March 2024, while total liabilities rose to 3,905.38 crore from 3,393.30 crore, indicating a stable financial position. The cash flow from operating activities also improved to 498 crore in March 2024, compared to 176 crore in March 2023, showcasing better cash generation capabilities. Overall, Akums Drugs demonstrated a strong recovery and growth trajectory in its financial performance over the past few years.

Are Akums Drugs & Pharmaceuticals Ltd latest results good or bad?

Akums Drugs & Pharmaceuticals Ltd's latest results show strong revenue growth and improved net profit, but low return on equity and stock underperformance raise concerns about capital efficiency. Overall, while there are positive signs, the mixed performance suggests caution.

Akums Drugs & Pharmaceuticals Ltd's latest results show a mixed picture. On one hand, the company reported net sales of ₹1,159.59 crores for the December quarter, which reflects a strong sequential growth of 13.96% and a year-on-year increase of 14.76%. Additionally, net profit surged to ₹66.32 crores, marking a significant 62.63% improvement from the previous quarter.<BR><BR>Operating margins also improved, rising to 12.66%, which is a positive sign of operational recovery. However, despite these improvements, the company's return on equity (ROE) remains low at 9.70%, which is below industry standards and raises concerns about capital efficiency. Furthermore, the stock has underperformed the broader market, declining 18.09% over the past year compared to the Sensex's gain of 8.52%.<BR><BR>In summary, while the recent quarterly results indicate operational improvements and revenue growth, the underlying issues related to profitability consistency and capital efficiency continue to pose challenges for the company. This mixed performance suggests that while there are positive signs, significant concerns remain, making the overall assessment somewhat cautious.

Should I buy, sell or hold Akums Drugs & Pharmaceuticals Ltd?

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 17-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price has risen slightly to 464.40, indicating a potential trend reversal after recent declines. Despite this short-term gain, the stock has underperformed over the past year, raising concerns about long-term growth prospects.

As of 17-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is rising slightly, with a current price of 464.40, reflecting a change of 0.2 (0.04%) upward. This increase comes after three consecutive days of decline, indicating a potential trend reversal. Despite the stock's recent performance, which shows a 1-week decline of 7.32% and a 1-month decline of 5.19%, today's performance aligns with the sector, suggesting a stabilization in the stock's movement.<BR><BR>The stock's liquidity remains adequate, with a delivery volume of 51.84k on 16 March, although this figure has decreased by 51.04% compared to the 5-day average. Additionally, the company has a low Debt to Equity ratio and an attractive valuation with a Price to Book Value of 2.3, which may contribute to investor confidence. Notably, institutional investors have increased their stake by 4% over the previous quarter, now holding 15.55% of the company, which indicates growing confidence from more sophisticated investors.<BR><BR>However, the stock has underperformed the market over the past year, generating a return of -8.50% compared to the market's positive return of 2.56%. This underperformance, coupled with low management efficiency reflected in a Return on Equity of 9.70%, suggests that while there may be short-term gains, long-term growth prospects remain a concern due to slow net sales growth and flat results in recent financial periods. Overall, the slight rise in stock price today appears to be a reaction to a potential trend reversal and increased institutional interest, despite the broader context of underperformance and management challenges.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 18-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is rising to 481.30, reflecting a 3.64% increase. This rise is driven by strong buying interest, increased institutional investor participation, and significant profit growth, despite a decline in delivery volume.

As of 18-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is rising, currently at 481.30, reflecting a change of 16.9 (3.64%) increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.37% today and has experienced consecutive gains over the last two days, accumulating a total return of 3.68% during this period. Additionally, the stock reached an intraday high of Rs 485, indicating strong buying interest.<BR><BR>Moreover, there has been an increase in participation from institutional investors, who have raised their stake by 4% in the previous quarter, now holding 15.55% of the company. This trend suggests a growing confidence among more sophisticated investors regarding the company's fundamentals. Despite the stock's negative performance over the past year, where it has generated a return of -6.77%, its profits have significantly increased by 1362%, which may indicate potential for future growth.<BR><BR>However, it is important to note that the stock's delivery volume has decreased by 29.73% compared to the 5-day average, suggesting a decline in investor participation. Despite this, the overall positive sentiment from institutional investors and recent performance improvements contribute to the stock's current rise.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 19-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is at 468.15, down 2.94%. The decline is due to underperformance in its sector, a trend reversal after previous gains, and waning investor participation, compounded by low return on equity and concerning long-term growth prospects.

As of 19-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is falling, currently at 468.15, reflecting a decrease of 14.2 points or 2.94%. This decline is attributed to several factors. The stock has underperformed its sector by 0.79% today and has experienced a trend reversal after two consecutive days of gains. It opened with a loss of 2% and reached an intraday low of Rs 465, marking a 3.6% drop.<BR><BR>In terms of broader performance, the stock has shown a negative return of 6.06% over the past week and 3.79% over the past month, while the benchmark Sensex has declined by 2.40% and 10.05%, respectively. Additionally, the pharmaceuticals and drugs sector has also fallen by 2.11%. <BR><BR>Investor participation appears to be waning, as evidenced by a significant drop in delivery volume, which fell by 50.22% compared to the 5-day average. Although institutional investors have increased their stake by 4% over the previous quarter, the overall sentiment remains cautious due to the company's low return on equity (ROE) of 9.7%, indicating poor management efficiency and profitability. <BR><BR>Furthermore, the company's long-term growth prospects are concerning, with net sales growing at an annual rate of only 6.10% and operating profit at 17.54% over the last five years. These factors collectively contribute to the stock's current downward trajectory.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 20-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price has risen to 484.50, reflecting a 3.33% increase, driven by strong relative performance, positive trading momentum, and increased institutional investor participation. Despite a year-over-year return of -4.06%, significant profit growth and favorable valuations enhance the stock's appeal, although declining delivery volume raises some concerns.

As of 20-Mar, Akums Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 484.50, reflecting a change of 15.6 (3.33%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 1.63% today, indicating strong relative performance. Additionally, it reached an intraday high of Rs 487.75, which is a 4.02% increase, suggesting positive trading momentum.<BR><BR>The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bullish trend. Furthermore, there has been an increase in participation from institutional investors, who have raised their stake by 4% over the previous quarter, now holding 15.55% of the company. This suggests a growing confidence among more sophisticated investors regarding the company's fundamentals.<BR><BR>Despite a year-over-year return of -4.06%, the company's profits have surged by 1362%, indicating a significant improvement in profitability, which may be attracting investor interest. The low Debt to Equity ratio and attractive valuation with a Price to Book Value of 2.4 also contribute positively to the stock's appeal.<BR><BR>However, it is important to note that there has been a decline in delivery volume, which fell by 29.06% against the 5-day average, indicating a potential concern regarding investor participation. Nevertheless, the overall positive factors seem to outweigh the negatives at this time, contributing to the stock's rise.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 23-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is at Rs 467.80, down 3.3%, influenced by underperformance against the market and a significant drop in investor participation. Despite some positive factors, overall sentiment remains negative due to poor management efficiency and slow growth prospects.

As of 23-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is falling, currently at Rs 467.80, which reflects a decrease of Rs 15.95 or 3.3%. This decline is influenced by several factors. The stock has underperformed compared to the broader market, with a 1-month return of -1.41% against a -12.72% decline in the Sensex. Additionally, the stock's performance today shows it has outperformed its sector by only 0.27%, while the Pharmaceuticals & Drugs sector has fallen by 3.62%.<BR><BR>The stock also touched an intraday low of Rs 463, indicating a significant drop of 4.29% during the trading day. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 15.78% compared to the 5-day average. This suggests a lack of confidence among investors, contributing to the stock's downward movement.<BR><BR>Despite some positive factors, such as a low debt-to-equity ratio and an increase in institutional investor participation, the overall sentiment remains negative due to poor management efficiency, as indicated by a low return on equity (ROE) of 9.7%. The company's long-term growth prospects are also concerning, with net sales growing at an annual rate of only 6.10% over the last five years. These elements combined have led to the current decline in the stock price.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 24-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 477.45, reflecting a 2.06% increase due to strong trading performance, increased investor interest, low financial risk, and rising institutional stakes.

As of 24-Mar, Akums Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 477.45, which reflects a change of Rs 9.65 or 2.06% increase. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed its sector by 0.94% today, indicating stronger performance relative to its peers. Additionally, the stock reached an intraday high of Rs 482.05, showing positive momentum within the trading day. The delivery volume has also increased by 15.36% compared to the 5-day average, suggesting rising investor participation and interest in the stock.<BR><BR>Moreover, the company has a low Debt to Equity ratio at 0 times, which is favorable for investors as it indicates lower financial risk. The return on equity (ROE) stands at 9.7%, and despite being considered low, it is coupled with a significant increase in profits by 1362% over the past year, which enhances the stock's attractiveness. Institutional investors have increased their stake by 4% in the previous quarter, now holding 15.55% of the company, reflecting confidence from more sophisticated investors in the company's fundamentals.<BR><BR>In summary, the combination of positive trading performance, increased investor participation, low financial risk, and rising institutional interest contributes to the current rise in the stock price of Akums Drugs & Pharmaceuticals Ltd.

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 25-Mar, Akums Drugs & Pharmaceuticals Ltd is seeing a stock price increase to Rs 493.30, driven by strong recent performance, heightened investor interest, and solid financial fundamentals, including a significant profit surge of 1362% over the past year.

As of 25-Mar, Akums Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 493.30, reflecting an increase of Rs 15.85 or 3.32%. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed the sector by 1.43% today and has shown a consecutive gain over the last two days, with a total return of 5.45% during this period. Additionally, the stock reached an intraday high of Rs 497.8, marking a 4.26% increase at its peak. <BR><BR>Moreover, Akums Drugs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend. There has also been a notable increase in investor participation, with delivery volume rising by 6.23% compared to the 5-day average, suggesting growing interest in the stock.<BR><BR>Institutional investors have increased their stake by 4% over the previous quarter, now holding 15.55% of the company. This influx of institutional investment often reflects confidence in the company's fundamentals, which can positively influence stock performance. <BR><BR>Financially, the company has a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 2.5. Over the past year, while the stock generated a return of 5.02%, its profits have surged by an impressive 1362%, further supporting the stock's upward trajectory. <BR><BR>In summary, the combination of strong recent performance, increased investor participation, and solid financial fundamentals are key reasons for the rising stock price of Akums Drugs & Pharmaceuticals Ltd.

Which are the latest news on Akums Drugs?